Omeros Corporation (OMER)
| Market Cap | 1.06B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.35M |
| Shares Out | 72.00M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,618,034 |
| Open | 14.65 |
| Previous Close | 14.74 |
| Day's Range | 14.30 - 14.89 |
| 52-Week Range | 2.95 - 17.65 |
| Beta | 2.53 |
| Analysts | Strong Buy |
| Price Target | 32.50 (+121.54%) |
| Earnings Date | May 14, 2026 |
About OMER
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OMER stock is "Strong Buy." The 12-month stock price target is $32.5, which is an increase of 121.54% from the latest price.
News
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding Sys...
Omeros Earnings Call Transcript: Q4 2025
Q4 2025 saw a transformative asset sale to Novo Nordisk and FDA approval plus rapid U.S. launch of YARTEMLEA, driving a swing to profitability and strengthening the balance sheet. Early YARTEMLEA adoption is robust, with strong payer and formulary support.
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, whi...
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026...
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantatio...
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ca...
Omeros Announces First Commercial Sales of YARTEMLEA®
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orde...
Omeros prices transplant complication drug at $36,000 per dose
Omeros will price its recently approved drug for a life-threatening transplant complication in adults and children aged two and older at $36,000 per single-dose vial, CEO Gregory Demopulos said on a c...
Omeros Transcript: FDA Announcement
YARTEMLEA received FDA approval as the first therapy for TA-TMA, showing strong efficacy and a favorable safety profile. The launch is expected to shift treatment paradigms, with broad label coverage, robust reimbursement support, and a focus on early intervention and outpatient use.
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and on...
US FDA approves Omeros' drug to treat dangerous transplant complication
The U.S. Food and Drug Administration has approved Omeros' drug for a dangerous transplant complication, marking the first treatment to be greenlit for the condition, the company said on Wednesday.
FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoiet...
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (...
Omeros Earnings Call Transcript: Q3 2025
Q3 2025 saw a net loss of $30.9M, with adjusted net loss at $22.1M. A major Novo Nordisk deal for Zaltenibart is set to bring $240M upfront, supporting debt repayment and the Yartemlya launch, which awaits FDA approval by year-end.
Omeros Corporation Reports Third Quarter 2025 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which includ...
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025,...
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing ...
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on We...
Can OMER stock retain Novo Nordisk driven gains over the long-term?
Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER's...
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disord...
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they have entered into a definitive asset purchase and license agreement fo...
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and...
Omeros Earnings Call Transcript: Q2 2025
Q2 2025 net loss narrowed to $25.4M, with cash bolstered by a $20.6M offering and major debt reduction. Narsoplimab's FDA review is ongoing, with a PDUFA date set for December, and advanced partnership talks could provide significant upfront capital.